SCHEMBL18426446

SCHEMBL18426446

Cc1cc(=O)[nH]c(SCC(=O)c2ccc(Cl)c(S(N)(=O)=O)c2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 12/20 1.00
▸ CA2 P00918 12/20 1.00
▸ CA7 P43166 12/20 1.00
▸ CA13 Q8N1Q1 12/20 1.00
▸ CA12 O43570 10/20 1.00
▸ CA6 P23280 10/20 1.00
▸ HDAC6 Q9UBN7 4/20 0.67
▸ HDAC3 O15379 1/20 0.67
▸ HDAC1 Q13547 1/20 0.67
▸ HDAC2 Q92769 1/20 0.67
▸ POLB P06746 1/20 0.66
▸ HSP90AA1 P07900 1/20 0.66
▸ HSP90AB1 P08238 1/20 0.66
▸ GAA P10253 1/20 0.66
▸ L3MBTL1 Q9Y468 1/20 0.66
▸ LMNA P02545 2/20 0.64
▸ TSHR P16473 1/20 0.64
▸ CYP1A2 P05177 1/20 0.64
▸ CYP2C9 P11712 1/20 0.64
▸ CYP2C19 P33261 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18425013 0.88 CA1 (1.00) CA1CA2CA7CA13CA12
SCHEMBL20454818 0.86 CA1 (1.00) CA1CA2CA7CA13CA12
SCHEMBL18425027 0.82 CA1 (1.00) CA1CA2CA7CA13CA12
SCHEMBL17382815 0.80 HDAC6 (1.00) CA1CA2CA7CA13CA12
SCHEMBL18425075 0.79 CA1 (1.00) CA1CA2CA7CA13CA12
SCHEMBL18426071 0.78 CA1 (1.00) CA1CA2CA7CA13CA12
SCHEMBL17382991 0.78 CYP1A2 (1.00) CA1CA2CA7CA13CA12
SCHEMBL18425601 0.77 CA1 (0.85) CA1CA2CA7CA13CA12
SCHEMBL17383001 0.75 ALDH1A1 (1.00) CA1CA2CA7CA13CA12
SCHEMBL18426434 0.75 CA1 (1.00) CA1CA2CA7CA13CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180222856-A1 SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE VILNIUS UNIVERSITY (LT) 2018-08-09 — — US claimed
EP-3328833-B1 SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE UNIV VILNIUS (LT) 2025-08-06 — — EP disclosed
US-11312682-B2 Selective inhibitors of carbonic anhydrase VILNIUS UNIVERSITY (LT) 2022-04-26 — — US disclosed
US-20180222856-A1 SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE VILNIUS UNIVERSITY (LT) 2018-08-09 — — US disclosed
EP-3328833-A1 SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE Vilnius University (LT) 2018-06-06 — — EP disclosed
WO-2017017505-A1 SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE VILNIUS UNIVERSITY (LT) 2017-02-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312682-B2 Selective inhibitors of carbonic anhydrase CA2, CA9, CA7 CA1 6/4885CA2 1/4885CA7 3/4885
US-20180222856-A1 SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE CA9, CA2, CA7 CA1 6/4885CA2 2/4885CA7 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback